메뉴 건너뛰기




Volumn 12, Issue 3, 2010, Pages 186-199

Parkinson's disease and motor fluctuations

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; APOMORPHINE; AROMATIC LEVO AMINO ACID DECARBOXYLASE; ASCORBIC ACID; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; LISURIDE; MONOAMINE OXIDASE B INHIBITOR; PRAMIPEXOLE; RASAGILINE; RILUZOLE; ROPINIROLE; ROTIGOTINE; SARIZOTAN; SELEGILINE; TOLCAPONE; TYROSINE 3 MONOOXYGENASE; VIRUS VECTOR; ZONISAMIDE;

EID: 77953540896     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-010-0067-8     Document Type: Review
Times cited : (12)

References (44)
  • 1
    • 0035353725 scopus 로고    scopus 로고
    • Frequency of levodopa related dyskinesias and motor fluctuations as estimated from the cumulative literature
    • Ahlskog JE, Muenter MD: Frequency of levodopa related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001, 16:448-458.
    • (2001) Mov Disord , vol.16 , pp. 448-458
    • Ahlskog, J.E.1    Muenter, M.D.2
  • 2
    • 0030804074 scopus 로고    scopus 로고
    • Ropinirole for the treatment of early Parkinson's disease. The ropinirole study group
    • Adler CH, Sethi KD, Hauser RA, et al.: Ropinirole for the treatment of early Parkinson's disease. The Ropinirole StudyGroup. Neurology 1997, 49:393-399.
    • (1997) Neurology , vol.49 , pp. 393-399
    • Adler, C.H.1    Sethi, K.D.2    Hauser, R.A.3
  • 3
    • 3142733662 scopus 로고    scopus 로고
    • Pramipexole vs levodopa as initial treatment for Parkinson's disease: A 4-year randomized-controlled trial
    • Holloway RG, Shoulson I, Fahn S, et al.: Pramipexole vs levodopa as initial treatment for Parkinson's disease: a 4-year randomized-controlled trial. Arch Neurol 2004, 61:1044-1053.
    • (2004) Arch Neurol , vol.61 , pp. 1044-1053
    • Holloway, R.G.1    Shoulson, I.2    Fahn, S.3
  • 4
    • 0033768218 scopus 로고    scopus 로고
    • Dyskinesias and motor fluctuations in Parkinson's disease A community-based study
    • Schrag A, Quinn N: Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 2000, 123:2297-2305.
    • (2000) Brain , vol.123 , pp. 2297-2305
    • Schrag, A.1    Quinn, N.2
  • 5
    • 2942541214 scopus 로고    scopus 로고
    • Striatal plasticity and extrapyramidal motor dysfunction
    • Chase TN: Striatal plasticity and extrapyramidal motor dysfunction. Parkinsonism Relat Disord 2004, 10:305-313.
    • (2004) Parkinsonism Relat Disord , vol.10 , pp. 305-313
    • Chase, T.N.1
  • 6
    • 53149097346 scopus 로고    scopus 로고
    • Preventing and controlling dyskinesia in Parkinson's disease-A view of current knowledge and future opportunities
    • Jenner P: Preventing and controlling dyskinesia in Parkinson's disease-a view of current knowledge and future opportunities. Mov Disord 2008, 23 (Suppl 3):585-598. This review discusses the pathophysiology of dyskinesias in Parkinson's disease, as well as currently available and potential future strategies of treatment and prevention. This review discusses the pathophysiology of dyskinesias in Parkinson's disease, as well as currently available and potential future strategies of treatment and prevention
    • (2008) Mov Disord , vol.23 , Issue.SUPPL. 3 , pp. 585-598
    • Jenner, P.1
  • 7
    • 18144376227 scopus 로고    scopus 로고
    • Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naïve primates
    • DOI 10.1002/mds.20317
    • Smith LA, Jackson MJ, Al-Barghouthy G, et al.: Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drugnaïve primates. Mov Disord 2005, 20:306-314. (Pubitemid 40613291)
    • (2005) Movement Disorders , vol.20 , Issue.3 , pp. 306-314
    • Smith, L.A.1    Jackson, M.J.2    Al-Barghouthy, G.3    Rose, S.4    Kuoppamaki, M.5    Olanow, W.6    Jenner, P.7
  • 8
    • 77953542862 scopus 로고    scopus 로고
    • Presented at the 13th International Congress of Parkinson's Disease and Movement Disorders. Paris France
    • Stocchi F, Kakarieka A, Kieburtz K, et al.: The STRIDEPD (Stalevo Reduction in Dyskinesia Evaluation) study [abstract LB-19]. Presented at the 13th International Congress of Parkinson's Disease and Movement Disorders. Paris, France; June 7-11, 2009. Available at http://www.movementdisorders.org/ congress/ congress09/late-breaking-abstracts.pdf.
    • (2009) The STRIDEPD (Stalevo Reduction in Dyskinesia Evaluation) study [abstract LB-19]
    • Stocchi, F.1    Kakarieka, A.2    Kieburtz, K.3
  • 9
    • 0023765002 scopus 로고
    • Practical application of a lowprotein diet for Parkinson's disease
    • Riley D, Lang AE: Practical application of a lowprotein diet for Parkinson's disease. Neurology 1988, 38:1026-1031.
    • (1988) Neurology , vol.38 , pp. 1026-1031
    • Riley, D.1    Lang, A.E.2
  • 10
    • 0029732865 scopus 로고    scopus 로고
    • Liquid levodopa/carbidopa produces significant improvement in motor function without dyskinesia exacerbation
    • Pappert EJ, Goetz CG, Niederman F, et al.: Liquid levodopa/carbidopa produces significant improvement in motor function without dyskinesia exacerbation. Neurology 1996, 47(6):1493-1495.
    • (1996) Neurology , vol.47 , Issue.6 , pp. 1493-1495
    • Pappert, E.J.1    Goetz, C.G.2    Niederman, F.3
  • 11
    • 85047657919 scopus 로고    scopus 로고
    • Parcopa: A rapidly dissolving formulation of carbidopa/levodopa
    • Parcopa: a rapidly dissolving formulation of carbidopa/ levodopa. Med Lett Drugs Ther 2005, 47 (1201):12.
    • (2005) Med Lett Drugs Ther , vol.47 , Issue.1201 , pp. 12
  • 12
    • 19744378296 scopus 로고    scopus 로고
    • Levodopa and the progression of Parkinson's disease
    • Parkinson Study Group
    • Fahn S, Oakes D, Shoulson I, Parkinson Study Group, et al.: Levodopa and the progression of Parkinson's disease. N Engl J Med 2004, 351 (24):2498-2508.
    • (2004) N Engl J Med , vol.351 , Issue.24 , pp. 2498-2508
    • Fahn, S.1    Oakes, D.2    Shoulson, I.3
  • 14
    • 70349657144 scopus 로고    scopus 로고
    • Impulse control disorders and dopamine dysregulation syndrome associated with dopamine agonist therapy in Parkinson's disease
    • Parkinson's Disease and Motor Fluctuations Hinson 197 This article presents a detailed review of an important complication of dopamine agonist therapy
    • Fenu S, Wardas J, Morelli M: Impulse control disorders and dopamine dysregulation syndrome associated with dopamine agonist therapy in Parkinson's disease. Behav Pharmacol 2009, 20(5- 6):363-379. Parkinson's Disease and Motor Fluctuations Hinson 197 This article presents a detailed review of an important complication of dopamine agonist therapy.
    • (2009) Behav Pharmacol , vol.20 , Issue.5-6 , pp. 363-379
    • Fenu, S.1    Wardas, J.2    Morelli, M.3
  • 15
    • 0030753601 scopus 로고    scopus 로고
    • Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebocontrolled, parallel-group study
    • Lieberman AN, Ranhosky A, Korts D: Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebocontrolled, parallel-group study. Neurology 1997, 49:162-168.
    • (1997) Neurology , vol.49 , pp. 162-168
    • Lieberman, A.N.1    Ranhosky, A.2    Korts, D.3
  • 16
    • 0031664919 scopus 로고    scopus 로고
    • A multicenter trial of ropinirole as an adjunct treatment for Parkinson's disease
    • Lieberman AN, Olanow CW, Sethi K, et al.: A multicenter trial of ropinirole as an adjunct treatment for Parkinson's disease. Neurology 1998, 51:1057-1062.
    • (1998) Neurology , vol.51 , pp. 1057-1062
    • Lieberman, A.N.1    Olanow, C.W.2    Sethi, K.3
  • 17
    • 34848821970 scopus 로고    scopus 로고
    • Tolcapone 2007: An efficacy and safety review
    • Olanow CW, Watkins PB: Tolcapone 2007: an efficacy and safety review. J Clin Neuropharm 2007, 30:287-294.
    • (2007) J Clin Neuropharm , Issue.30 , pp. 287-294
    • Olanow, C.W.1    Watkins, P.B.2
  • 18
    • 0030778373 scopus 로고    scopus 로고
    • Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients
    • Parkinson Study Group
    • Parkinson Study Group: Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 1997, 42(5):747-755.
    • (1997) Ann Neurol , vol.42 , Issue.5 , pp. 747-755
  • 19
    • 0031773064 scopus 로고    scopus 로고
    • Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations nomecomt study group
    • Rinne UK, Larsen JP, Siden A, Worm-Petersen J: Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology 1998, 51 (5):1309-1314.
    • (1998) Neurology , vol.51 , Issue.5 , pp. 1309-1314
    • Rinne, U.K.1    Larsen, J.P.2    Siden, A.3    Worm-Petersen, J.4
  • 20
    • 3242784708 scopus 로고
    • Deprenyl in the treatment of symptom fluctuation in advanced Parkinson's disease
    • Golbe LI, Lieberman AN, Muenter MD, et al.: Deprenyl in the treatment of symptom fluctuation in advanced Parkinson's disease. Clin Neuropharmacol 1988, 11:45-55.
    • (1988) Clin Neuropharmacol , vol.11 , pp. 45-55
    • Golbe, L.I.1    Lieberman, A.N.2    Muenter, M.D.3
  • 21
    • 13444302612 scopus 로고    scopus 로고
    • A randomized placebocontrolled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations. The PRESTO study
    • Parkinson Study Group
    • Parkinson Study Group: A randomized placebocontrolled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations. The PRESTO study. Arch Neurol 2005, 62 (2):241-248.
    • (2005) Arch Neurol , vol.62 , Issue.2 , pp. 241-248
  • 22
    • 33750296512 scopus 로고    scopus 로고
    • Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline
    • de Marcaida JA, Schwid SR, White WB, et al.: Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline. Mov Disord 2006, 21(10):1716-1721.
    • (2006) Mov Disord , vol.21 , Issue.10 , pp. 1716-1721
    • De Marcaida, J.A.1    Schwid, S.R.2    White, W.B.3
  • 24
    • 4243089926 scopus 로고    scopus 로고
    • Parkinson's disease: Surgical options
    • Bronte-Stewart H: Parkinson's disease: surgical options. Curr Treat Options Neurol 2003, 5(2):131-147.
    • (2003) Curr Treat Options Neurol , vol.5 , Issue.2 , pp. 131-147
    • Bronte-Stewart, H.1
  • 25
    • 67649872392 scopus 로고    scopus 로고
    • Risk factors for hemorrhage during microelectrode-guided deep brain stimulation and the introduction of an improved microelectrode design
    • Ben-Haim S, Asaad WF, Gale JT, et al.: Risk factors for hemorrhage during microelectrode-guided deep brain stimulation and the introduction of an improved microelectrode design. Neurosurgery 2009, 64 (4):754-762.
    • (2009) Neurosurgery , vol.64 , Issue.4 , pp. 754-762
    • Ben-Haim, S.1    Asaad, W.F.2    Gale, J.T.3
  • 26
    • 38049079782 scopus 로고    scopus 로고
    • Prospective comparative study on cost-effectiveness of subthalamic stimulation and best medical treatment in advanced Parkinson's disease
    • This is an open, prospective, longitudinal study designed to compare two cohorts of patients with advanced Parkinson's disease, one undergoing bilateral subthalamic deep brain stimulation and the other one receiving best medical treatment, with respect to the clinical effects observed and the medical expenses produced
    • Valldeoriola F, Morsi O, Tolosa E, et al.: Prospective comparative study on cost-effectiveness of subthalamic stimulation and best medical treatment in advanced Parkinson's disease. Mov Disord 2007, 22(15):2183-2191. This is an open, prospective, longitudinal study designed to compare two cohorts of patients with advanced Parkinson's disease, one undergoing bilateral subthalamic deep brain stimulation and the other one receiving best medical treatment, with respect to the clinical effects observed and the medical expenses produced.
    • (2007) Mov Disord , vol.22 , Issue.15 , pp. 2183-2191
    • Valldeoriola, F.1    Morsi, O.2    Tolosa, E.3
  • 27
    • 33645577588 scopus 로고    scopus 로고
    • Clinical and economic results of bilateral subthalamic nucleus stimulation in Parkinson's disease
    • SPARK Study Group
    • Fraix V, Houeto JL, Lagrange C, SPARK Study Group, et al.: Clinical and economic results of bilateral subthalamic nucleus stimulation in Parkinson's disease. J Neurol Neurosurg Psychiatry 2006, 77(4):443-449.
    • (2006) J Neurol Neurosurg Psychiatry , vol.77 , Issue.4 , pp. 443-449
    • Fraix, V.1    Houeto, J.L.2    Lagrange, C.3
  • 28
    • 0036723589 scopus 로고    scopus 로고
    • Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease
    • Stocchi F, Ruggieri S, Vacca L, et al.: Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. Brain 2002, 125(9):2058-2066.
    • (2002) Brain , vol.125 , Issue.9 , pp. 2058-2066
    • Stocchi, F.1    Ruggieri, S.2    Vacca, L.3
  • 29
    • 12544252127 scopus 로고    scopus 로고
    • Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease
    • Nyholm D, Nilsson Remahl AI, Dizdar N, et al.: Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005, 64(2):216-223.
    • (2005) Neurology , vol.64 , Issue.2 , pp. 216-223
    • Nyholm, D.1    Nilsson Remahl, A.I.2    Dizdar, N.3
  • 30
    • 52649108045 scopus 로고    scopus 로고
    • Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: A multicenter study
    • This study demonstrates the evolution of 82 patients with PD and severe motor fluctuations, who received long-term treatment with continuous subcutaneous apomorphine infusion
    • Garcia Ruiz PJ, Sesar Ignacio A, Ares Pensado B, et al.: Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study. Mov Disord 2008, 23(8):1130-1136. This study demonstrates the evolution of 82 patients with PD and severe motor fluctuations, who received long-term treatment with continuous subcutaneous apomorphine infusion.
    • (2008) Mov Disord , vol.23 , Issue.8 , pp. 1130-1136
    • Garcia Ruiz, P.J.1    Sesar Ignacio, A.2    Ares Pensado, B.3
  • 31
    • 34248372064 scopus 로고    scopus 로고
    • Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: A double- blind, double-dummy, randomized controlled trial
    • SP 515 Investigators
    • Poewe WH, Rascol O, Quinn N, SP 515 Investigators, et al.: Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double- blind, double-dummy, randomized controlled trial. Lancet Neurol 2007, 6(6):513-520.
    • (2007) Lancet Neurol , vol.6 , Issue.6 , pp. 513-520
    • Poewe, W.H.1    Rascol, O.2    Quinn, N.3
  • 32
    • 1442300051 scopus 로고    scopus 로고
    • Effect of riluzole on dyskinesia and duration of the on-state in Parkinson's disease patients: A double-blind, placebocontrolled pilot study
    • Braz CA, Borges V, Ferraz HB: Effect of riluzole on dyskinesia and duration of the on-state in Parkinson's disease patients: a double-blind, placebocontrolled pilot study. Clin Neuropharmacol 2004, 27:25-29.
    • (2004) Clin Neuropharmacol , vol.27 , pp. 25-29
    • Braz, C.A.1    Borges, V.2    Ferraz, H.B.3
  • 33
    • 0034090891 scopus 로고    scopus 로고
    • AMPA receptor blockade improves levodopa-induced dyskinesia in MTPT monkeys
    • Konitsiotis S, Blanchert PJ, Verhagen L, et al.: AMPA receptor blockade improves levodopa-induced dyskinesia in MTPT monkeys. Neurology 2000, 54:1589-1595.
    • (2000) Neurology , vol.54 , pp. 1589-1595
    • Konitsiotis, S.1    Blanchert, P.J.2    Verhagen, L.3
  • 34
    • 33644995350 scopus 로고    scopus 로고
    • A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia
    • Gardoni F, Picconi B, Ghiglieri V, et al.: A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia. J Neurosci 2006, 26(11):2914-2922.
    • (2006) J Neurosci , vol.26 , Issue.11 , pp. 2914-2922
    • Gardoni, F.1    Picconi, B.2    Ghiglieri, V.3
  • 35
    • 2342450729 scopus 로고    scopus 로고
    • Multicenter, open-label trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID study)
    • Olanow CW, Damier P, Goetz CG, et al.: Multicenter, open-label trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID study). Clin Neuropharmacol 2004, 27:58-62.
    • (2004) Clin Neuropharmacol , vol.27 , pp. 58-62
    • Olanow, C.W.1    Damier, P.2    Goetz, C.G.3
  • 36
    • 33847757879 scopus 로고    scopus 로고
    • Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double-blind, placebo-controlled trial
    • Goetz CG, Damier P, Hicking C, et al.: Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind, placebo-controlled trial. Mov Disord 2007, 22:179-186.
    • (2007) Mov Disord , vol.22 , pp. 179-186
    • Goetz, C.G.1    Damier, P.2    Hicking, C.3
  • 37
    • 1442276965 scopus 로고    scopus 로고
    • Novel therapeutic effects of the anticonvulsant, zonisamide, on Parkinson's disease
    • Murata M: Novel therapeutic effects of the anticonvulsant, zonisamide, on Parkinson's disease. Curr Pharm Des 2004, 10(6):687-693.
    • (2004) Curr Pharm Des , vol.10 , Issue.6 , pp. 687-693
    • Murata, M.1
  • 38
    • 33846054367 scopus 로고    scopus 로고
    • Japan Zonisamide on PD Study Group: Zonisamide improves motor function in Parkinson disease: A randomized, double-blind study
    • This multicenter, randomized, double-blind, paralleltreatment, placebo-controlled study evaluates the efficacy, safety, and tolerability of daily doses of 25, 50, and 198 Movement Disorders 100 mg of zonisamide administered as adjunctive treatment in patients with PD
    • Murata M,HasegawaK, Kanazawa I; Japan Zonisamide on PD Study Group: Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study. Neurology 2007, 68(1):45-50. This multicenter, randomized, double-blind, paralleltreatment, placebo-controlled study evaluates the efficacy, safety, and tolerability of daily doses of 25, 50, and 198 Movement Disorders 100 mg of zonisamide administered as adjunctive treatment in patients with PD.
    • (2007) Neurology , vol.68 , Issue.1 , pp. 45-50
    • Murata, M.1    Hasegawa, K.2    Kanazawa, I.3
  • 39
    • 23644462322 scopus 로고    scopus 로고
    • Openlabel pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease
    • Zesiewitz TA, Sullivan KL, Maldonado JL, et al.: Openlabel pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease. Mov Disord 2005, 20:1205-1209.
    • (2005) Mov Disord , vol.20 , pp. 1205-1209
    • Zesiewitz, T.A.1    Sullivan, K.L.2    Maldonado, J.L.3
  • 40
    • 0042837887 scopus 로고    scopus 로고
    • A double blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease
    • Olanow CW, Goetz CG, Kordower JH, et al.: A double blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003, 54:403-414.
    • (2003) Ann Neurol , vol.54 , pp. 403-414
    • Olanow, C.W.1    Goetz, C.G.2    Kordower, J.H.3
  • 41
    • 43249114934 scopus 로고    scopus 로고
    • Lewy bodylike pathology in long-term embryonic nigral transplants in Parkinson's disease
    • Kordower JH, Chu Y, Hauser RA, et al.: Lewy bodylike pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 2008, 14(5):504-506.
    • (2008) Nat Med , vol.14 , Issue.5 , pp. 504-506
    • Kordower, J.H.1    Chu, Y.2    Hauser, R.A.3
  • 42
    • 2542478946 scopus 로고    scopus 로고
    • Implantation of Spheramine in advanced Parkinson's disease (PD)
    • Bakay RA, Raiser CD, Stover NP, et al.: Implantation of Spheramine in advanced Parkinson's disease (PD). Front Biosci 2004, 9:592-602.
    • (2004) Front Biosci , vol.9 , pp. 592-602
    • Bakay, R.A.1    Raiser, C.D.2    Stover, N.P.3
  • 43
    • 0036210202 scopus 로고    scopus 로고
    • Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adenoassociated viral vectors expressing dopaminesynthesizing enzymes
    • Muramatsu S, Fujimoto K, Ikeguchi K: Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adenoassociated viral vectors expressing dopaminesynthesizing enzymes. Hum Gene Ther 2002, 13:345-354.
    • (2002) Hum Gene Ther , vol.13 , pp. 345-354
    • Muramatsu, S.1    Fujimoto, K.2    Ikeguchi, K.3
  • 44
    • 41949110690 scopus 로고    scopus 로고
    • Safety and tolerability of intraputaminal delivery of CERE- 120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial
    • In this open-label study, 12 patients with PD received bilateral stereotactic intraputaminal injections of adenoassociated virus serotype 2-neurturin. The resulting initial data support the safety, tolerability, and potential efficacy of this treatment
    • Marks Jr WJ, Ostrem JL, Verhagen L, et al.: Safety and tolerability of intraputaminal delivery of CERE- 120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol 2008, 7 (5):400-408. In this open-label study, 12 patients with PD received bilateral stereotactic intraputaminal injections of adenoassociated virus serotype 2-neurturin. The resulting initial data support the safety, tolerability, and potential efficacy of this treatment.
    • (2008) Lancet Neurol , vol.7 , Issue.5 , pp. 400-408
    • Marks Jr., W.J.1    Ostrem, J.L.2    Verhagen, L.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.